Articles

Q&A: 'We all came from the sea…'

We speak to Mark Currie, CSO and president of R&D for Ironwood Pharmaceutical, about treatments for painful intestinal disorders and more.
Written byLloyd Dunlap
| 5 min read

According to Mark Currie, chief scientific officer and president of research and development at Ironwood Pharmaceutical Inc., “There is something indescribably special about creating a new drug that goes on to make a difference in people’s lives. Earlier in my career, I had been part of development teams that had created drugs for cardiovascular and central nervous system diseases, and I knew drug discovery was something I wanted to keep doing.”

So, we invited him to talk to us a bit about Ironwood and what treatments he’s helping to shepherd along there.

DDNews: What was your motivation for joining Ironwood?

Mark Currie: When I met the team at Ironwood, I could immediately tell they shared that passion. I came on board in 2002, just a few years after the company was formed out of MIT. It was extraordinary to have the opportunity to build and shape this nascent discovery team. From the beginning there was huge emphasis on drug hunting. We called ourselves “disciples of pharmacology,” and we started a “Great Drugmaking” lecture series where we brought in folks like Roy Vagelos from Merck and Nick Lydon, who had developed Gleevec, to tell us about their journeys. We immersed ourselves in the culture of drug discovery, and it wasn’t long before our team created the molecule that would one day be Ironwood’s first medicine, linaclotide.

DDNews: Can you tell us more about the first medicine you and your team developed at Ironwood?

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
A scientist in protective laboratory attire examines a sample under a microscope, surrounded by digital overlays of DNA strands, molecular structures, scientific symbols, and data graphics.
From automated experiments to AI-powered analysis, connected data, and smarter resource use, digital technologies are reshaping how scientists work — and what the laboratory itself can do.
Blue microscopic illustration of spherical cells with textured surfaces against a dark background.
Explore how longitudinal single-cell profiling of whole blood can reveal immune signatures associated with CAR T cell therapy-related neurotoxicity.